SNGX
SOLIGENIX, INC.
+0.02 (+5.50%)0.38USD242K成交股數8.3M市值–本益比(近四季)69.3股價營收比–營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | – | – | – | – | – | 2K-99% | 117K | 245K | 130K | 207K |
| 營業成本 | – | – | – | – | – | – | – | 2K | 117K | 222K | 110K | 184K |
| 毛利 | – | – | – | – | – | – | – | 0.00-100% | 0.00 | 23K | 20K | 23K |
| 毛利率 | – | – | – | – | – | – | – | 0.0% | 0.0% | 9.5% | 15.3% | 11.1% |
| 研發費用 | 974K | 1.8M | 2.3M | 1.6M | 1.7M | 1.9M | 969K | 501K | 1.1M | 778K | 826K | 763K |
| 銷售管理費用 | 1.1M | 1.1M | 1.2M | 997K | 1.1M | 1.1M | 897K | 1.2M | 1.0M | 1.4M | 973K | 891K |
| 營業利益 | −2.1M-24% | −2.9M-5% | −3.5M+86% | −2.6M+48% | −2.8M+31% | −3.0M+42% | −1.9M+5% | −1.7M+7% | −2.1M | −2.1M | −1.8M | −1.6M |
| 營業利益率 | – | – | – | – | – | – | – | -74,495.1% | -1,809.0% | -873.3% | -1,363.9% | -787.9% |
| 稅後淨利 | −2.0M-26% | −2.8M-4% | −2.9M+70% | −2.5M+54% | −2.7M+41% | −3.0M+66% | −1.7M+3% | −1.6M+2% | −1.9M | −1.8M | −1.7M | −1.6M |
| 淨利率 | – | – | – | – | – | – | – | -70,217.8% | -1,636.6% | -726.7% | -1,274.7% | -779.0% |
| 稀釋 EPS | -0.12-85% | -0.28-71% | 0.23-129% | -0.58-56% | -0.82-72% | -0.97-84% | -0.78-70% | -1.31-63% | -2.91 | -6.18 | -2.56 | -3.56 |
| 稀釋股數 | 16.0M | 10.2M | 5.2M | 4.3M | 3.3M | 3.0M | 2.2M | 1.3M | 658K | 485K | 649K | 453K |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 9.8M | 6.0M | 7.9M | 10.5M | 5.1M | 7.3M | 9.8M | 9.4M | 7.1M | 8.4M | 10.3M | 13.2M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 10.5M | 6.9M | 9.2M | 11.3M | 5.8M | 7.7M | 10.5M | 9.9M | 8.1M | 9.8M | 11.3M | 13.8M |
| 有息負債 | – | – | – | – | – | – | – | – | – | 1.0M | 1.4M | 2.1M |
| 總負債 | 3.9M | 3.8M | 3.9M | 3.7M | 3.9M | 3.8M | 4.5M | 6.4M | 7.3M | 7.3M | 7.1M | 8.0M |
| 股東權益 | 6.6M | 3.1M | 5.3M | 7.6M | 1.8M | 3.9M | 5.9M | 3.5M | 768K | 2.5M | 4.2M | 5.8M |
| 負債比 | 36.7% | 55.4% | 42.7% | 32.7% | 68.3% | 49.7% | 43.4% | 64.9% | 90.5% | 74.3% | 62.7% | 58.0% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | 7.4M | 8.9M | 11.1M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.4M+28% | – | – | – | −1.8M | – | – | −1.3M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2024 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2024 年度 · 119K
| Bio Therapeutics | 119K | 100.0% | -69.8% |
|---|
產品／服務2024 年度 · 119K
| Grant | 119K | 100.0% | -85.8% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | – | – | −11.1M | –% | -2.14 | −10.3M |
| FY2024 | 119K | -85.8% | −8.3M | -6,953.1% | -4.98 | – |
| FY2023 | 839K | -11.5% | −6.1M | -726.7% | -12.66 | – |
| FY2022 | 949K | +15.1% | −13.8M | -1,454.1% | -4.81 | – |
| FY2021 | 824K | -65.1% | −12.6M | -1,522.7% | -4.69 | – |
| FY2020 | 2.4M | -49.0% | −17.7M | -749.7% | -0.64 | – |
| FY2019 | 4.6M | -11.7% | −9.4M | -202.1% | -0.48 | – |
| FY2018 | 5.2M | – | −8.9M | -169.8% | -0.68 | – |